Author

M. Ladanyi

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 5

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 5 Organism:human· 5 Assay:bulk RNA-seq· 3 Research Focus:cancer & tumor microenvironment· 2 Research Focus:drug response / drug discovery· 2 Assay:ATAC-seq· 1 Research Focus:cell type annotation· 1 Research Focus:chromatin & epigenetic regulation· 1

Frequent Co-Authors

R. Somwar· 4 shared E. De Stanchina· 2 shared L. Spraggon· 2 shared W. Lockwood· 2 shared Y. Inoue· 2 shared A. A. Jungbluth· 1 shared A. B. Hartono· 1 shared A. D. Jayaprakash· 1 shared

Activity by Year

2018-2023 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 18 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

4 shared papersCancer Biology

R. Somwar

Mutual co-authors in cluster

Author profile →

5 papers

Recent·Most cited

Overcoming clinical resistance to EZH2 inhibition using rational epigenetic combination therapy

Y. Kazansky, D. Cameron, H. S. Mueller, P. Demarest, N. Zaffaroni, N. Arrighetti, V. Zuco, Y. Kuwahara, R. Somwar, M. Ladanyi, R. Qu, E. De Stanchina, F. S. Dela Cruz, A. L. Kung, M. Gounder, A. Kentsis

This study identifies mechanisms of resistance to EZH2 inhibition in SMARCB1-deficient cancers and proposes combination therapies to overcome resistance.

bioRxiv · Feb 6, 2023Cancer Biology

MEK inhibitor resistance in lung cancer cells associated with addiction to sustained ERK suppression

D. A. Farnsworth, Y. Inoue, F. D. Johnson, G. de Rappard-Yuswack, D. Lu, R. Shi, R. Somwar, M. Ladanyi, A. M. Unni, W. Lockwood

The paper identifies drug addiction to MEK inhibitors in KRAS-mutant lung cancer cells, showing that resistance is linked to ERK suppression and KRAS amplification, suggesting therapeutic strategies involving drug holidays.

bioRxiv · Apr 29, 2022 · PreprintCancer Biology

Extracellular signal-regulated kinase mediates chromatin rewiring and lineage transformation in lung cancer

Y. Inoue, A. Nikolic, D. Farnsworth, A. Liu, M. Ladanyi, R. Somwar, M. Gallo, W. Lockwood

This study identifies the ERK-CBP/p300-ETS axis as promoting lineage transformation between neuroendocrine and non-neuroendocrine lung cancer subtypes through chromatin rewiring.

bioRxiv · Nov 12, 2020Cancer Biology

Establishment of multiple novel patient-derived models of desmoplastic small round cell tumor enabling functional characterization of ERBB pathway signaling and pre-clinical evaluation of a novel targeted therapy approach

R. S. Smith, I. Odintsov, Z. Liu, T. Hayashi, A. J. W. Lui, M. Vojnic, Y. Suehara, M. S. Mattar, J. Hmeljak, H. A. Ramirez, M. Shaw, G. Bui, A. B. Hartono, E. Gladstone, H. Magnan, , R. Somwar

This study develops new DSRCT models and shows that targeting the ERBB pathway with EGFR inhibitors reduces tumor growth in preclinical models.

bioRxiv · Sep 22, 2020 · PreprintCancer Biology

YES1 amplification: a mechanism of acquired resistance to EGFR inhibitors identified by transposon mutagenesis and clinical genomics

P.-D. Fan, G. Narzisi, A. D. Jayaprakash, E. Venturini, N. Robine, P. Smibert, S. Germer, H. A. Yu, E. J. Jordan, P. K. Paik, Y. Y. Janjigian, J. E. Chaft, L. Wang, A. A. Jungbluth, S. Middha, , M. Ladanyi

This study identifies YES1 amplification as a novel mechanism of resistance to EGFR inhibitors in lung cancer using transposon mutagenesis and clinical genomic analysis.

bioRxiv · Mar 17, 2018Cancer Biology